Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

/ / News

Regeneron Pharmaceuticals Inc. said initial data from its Phase 1/2/3 clinical trial of its antibody cocktail in hospitalized COVID-19 patients requiring low-flow oxygen passed a futility analysis, meaning there was sufficient efficacy to warrant continuing the trial. “The results passed the futility analysis (p
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.